-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Leede Jones Gab Weighs in on ProMIS Neurosciences, Inc.'s FY2022 Earnings (TSE:PMN)
Leede Jones Gab Weighs in on ProMIS Neurosciences, Inc.'s FY2022 Earnings (TSE:PMN)
ProMIS Neurosciences, Inc. (TSE:PMN – Get Rating) – Research analysts at Leede Jones Gab boosted their FY2022 earnings per share estimates for shares of ProMIS Neurosciences in a research note issued on Monday, November 14th. Leede Jones Gab analyst D. Loe now forecasts that the company will post earnings of ($1.63) per share for the year, up from their previous estimate of ($1.87). The consensus estimate for ProMIS Neurosciences' current full-year earnings is ($2.73) per share. Leede Jones Gab also issued estimates for ProMIS Neurosciences' FY2023 earnings at ($1.81) EPS, FY2024 earnings at ($1.44) EPS, FY2025 earnings at ($1.90) EPS, FY2025 earnings at ($1.90) EPS and FY2026 earnings at ($1.94) EPS.
Get ProMIS Neurosciences alerts:ProMIS Neurosciences Price Performance
PMN stock opened at C$8.10 on Thursday. The stock has a 50-day moving average price of C$7.88 and a two-hundred day moving average price of C$5.69. The company has a current ratio of 5.42, a quick ratio of 4.81 and a debt-to-equity ratio of 108.33. ProMIS Neurosciences has a 1 year low of C$5.70 and a 1 year high of C$12.22. The stock has a market cap of C$69.49 million and a PE ratio of -426.32.
ProMIS Neurosciences (TSE:PMN – Get Rating) last announced its earnings results on Monday, November 14th. The company reported C($1.11) EPS for the quarter.ProMIS Neurosciences Company Profile
(Get Rating)
ProMIS Neurosciences, Inc discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Featured Stories
- MarketBeat: Week in Review 11/14 – 11/18
- Target's Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML's November Rally Have Staying Power?
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
ProMIS Neurosciences, Inc. (TSE:PMN – Get Rating) – Research analysts at Leede Jones Gab boosted their FY2022 earnings per share estimates for shares of ProMIS Neurosciences in a research note issued on Monday, November 14th. Leede Jones Gab analyst D. Loe now forecasts that the company will post earnings of ($1.63) per share for the year, up from their previous estimate of ($1.87). The consensus estimate for ProMIS Neurosciences' current full-year earnings is ($2.73) per share. Leede Jones Gab also issued estimates for ProMIS Neurosciences' FY2023 earnings at ($1.81) EPS, FY2024 earnings at ($1.44) EPS, FY2025 earnings at ($1.90) EPS, FY2025 earnings at ($1.90) EPS and FY2026 earnings at ($1.94) EPS.
Promis神经科学公司(多伦多证券交易所股票代码:PMN-GET Rating)-在11月14日星期一发布的一份研究报告中,Leeed Jones Gab的研究分析师上调了对Promis神经科学公司股票2022财年每股收益的预期。Leeed Jones Gab分析师D.Loe现在预测,该公司今年的每股收益将达到1.63美元,高于之前预测的1.87美元。对Promis神经科学公司目前全年收益的普遍估计是每股2.73美元。利德·琼斯·加布还发布了对PROMIS神经科学公司2023财年每股收益为1.81美元、2024财年每股收益为1.44美元、2025财年每股收益为1.90美元、2025财年每股收益为1.90美元和2026财年每股收益为1.94美元的预期。
ProMIS Neurosciences Price Performance
Promis神经科学的性价比
PMN stock opened at C$8.10 on Thursday. The stock has a 50-day moving average price of C$7.88 and a two-hundred day moving average price of C$5.69. The company has a current ratio of 5.42, a quick ratio of 4.81 and a debt-to-equity ratio of 108.33. ProMIS Neurosciences has a 1 year low of C$5.70 and a 1 year high of C$12.22. The stock has a market cap of C$69.49 million and a PE ratio of -426.32.
PMN股票周四开盘报8.10加元。该股的50日移动均线价格为7.88加元,200日移动均线价格为5.69加元。该公司的流动比率为5.42%,速动比率为4.81%,债务权益比率为108.33。Promis NeuroSciences的一年低点为5.70加元,一年高位为12.22加元。该股市值为6,949万加元,市盈率为-426.32。
ProMIS Neurosciences Company Profile
Promis神经科学公司简介
(Get Rating)
(获取评级)
ProMIS Neurosciences, Inc discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Promis神经科学公司发现和开发用于治疗神经退行性疾病的精确医学解决方案,主要是加拿大的阿尔茨海默病(AD)、肌萎缩侧索硬化症(ALS)和多系统萎缩(MSA)。该公司的专有发现平台包括PROMIS和Collective坐标算法,用于预测错误折叠蛋白质分子表面上被称为疾病特异性表位的新靶点。
Featured Stories
专题报道
- MarketBeat: Week in Review 11/14 – 11/18
- Target's Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML's November Rally Have Staying Power?
- MarketBeat:回顾一周11/14-11/18
- 目标的双重底部可能刚刚得到确认
- 美联储能涨到多高?如何进行交易
- Verra移动库存已返回空间站
- ASML的11月拉力赛有后劲吗?
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受PROMIS神经科学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Promis神经科学和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧